Healthcare · Biotechnology · NASDAQ

Immunitybio Inc (IBRX) Stock Price, Analysis & Trade Signals

$6.98-0.13 (-1.76%)

ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell)…

IBRX key stats

Market Cap
$7.39B
P/E Ratio
0
Forward P/E
86.21
EPS
-1.06
52 Week Range
$0.00 – $12.43
50-Day Avg
8.74
200-Day Avg
7.96
Revenue (TTM)
$182.57M
Revenue Growth (Qtr YoY)
52.3%
Profit Margin
0%
Operating Margin (TTM)
-159.7%
Beta
0.17
Volume
10.51M
30-Day Avg Volume
12.5M
CEO
Richard Gerald Adcock
Employees
688
IPO Date
Jul 28, 2015

IBRX on X: what traders are saying

  • Antonio Linares @alc2022 · Nov 4, 2026

    Companies with no actual competition: 1. $PLTR 2. $DUOL 3. $HIMS 4. $TSLA 5. $SPOT 6. $NAUT 7. $IBRX

  • Antonio Linares @alc2022 · Oct 27, 2026

    Learn the mental framework behind my $AMD, $PLTR, $NAUT and $IBRX picks https://t.co/XnYjPjtXxK

  • Retail Mourinho @retail_mourinho · Oct 23, 2026

    THE FINX MARKET GUIDE FOR BEGINNERS A watchlist by sector and theme. Neoclouds & AI Compute $NBIS $IREN $CRWV Photonics & AI Connectivity $AAOI $CRDO $LITE $COHR $ALAB Space $ASTS $RKLB $SPCX $FLY $VOYG Biotech & Life Sciences $NAUT $ABCL $IBRX Robotics & Automation $OUST…

  • Antonio Linares @alc2022 · Oct 21, 2026

    Companies with no actual competition: 1. $PLTR 2. $DUOL 3. $AMD 4. $SPOT 5. $HIMS 6. $TSLA 7. $NAUT 8. $IBRX

  • Antonio Linares @alc2022 · Oct 20, 2026

    I think this AI<>Biology basket will destroy the market over the next 10 years: $IBRX: the operating system of the immune system $NAUT: the $TSLA of proteomics $RXRX: superhuman Biology-Chemistry AI $ABCL: the machine that can hit any target in the body $HIMS: the dominant D2C

  • Wayne Liang @wliang · Oct 19, 2026

    Perfect bounce off the gold zone support on $ARKG ETF. Higher-beta biotech plays like $MRNA, $IBRX, $NAUT (and more) should soar if momentum persists. It's good to be cautious right now, but I'll keep sharing updates as we go! https://t.co/RFeUFRBJX6

IBRX analyst rating & price target

4 analysts rate IBRX Buy on consensus.

1Strong Buy
3Buy
0Hold
0Sell
0Strong Sell

Consensus price target: $14.25 (+104.3% upside from $6.98)

Recent IBRX insider transactions

InsiderDateTransactionSharesValue
Simon Barry J.
director
Oct 5, 2026Sale25,000$268.76K
Selecky Christobel
director
Jun 30, 2026Sale1,000$9K
Selecky Christobel
director
Jun 29, 2026Sale95,722$862.22K
Simon Barry J.
director
Jun 24, 2026Sale25,000$196.91K
Simon Barry J.
director
Jun 4, 2026Sale23,033$165.31K

Immunitybio Inc annual revenue & net income

Fiscal yearRevenueRevenue YoYNet income
2025$113.29M+668.31%$-351.4M
2024$14.75M+2270.58%$-413.56M
2023$622K+159.17%$-583.2M

Latest IBRX news

Stock data for IBRX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics